C. Boss

发表

Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.

L. Prade, A. Treiber, S. Delahaye, 2009, Journal of medicinal chemistry.

New classes of potent and bioavailable human renin inhibitors.

L. Prade, A. Treiber, S. Delahaye, 2009, Bioorganic & medicinal chemistry letters.

Inhibitors of Plasmepsin II-potential antimalarial agents.

L. Prade, G. Dunet, R. Brun, 2004, Bioorganic & medicinal chemistry letters.

The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders

C. Brotschi, A. Treiber, M. Raumer, 2020, ChemMedChem.

Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

M. Bolli, M. Iglarz, M. Clozel, 2008, Journal of Pharmacology and Experimental Therapeutics.

The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.

M. Bolli, M. Iglarz, M. Clozel, 2012, Journal of medicinal chemistry.

Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold‐Hopping Approach

M. Bolli, C. Brotschi, Stefan Abele, 2016, ChemMedChem.

Structure-activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2.

R. Koberstein, T. Weller, T. Sifferlen, 2013, Bioorganic & medicinal chemistry letters.

Synthesis, structure-activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1.

R. Koberstein, T. Weller, T. Sifferlen, 2013, Bioorganic & medicinal chemistry letters.

Novel pyrazolo-tetrahydropyridines as potent orexin receptor antagonists.

R. Koberstein, T. Weller, T. Sifferlen, 2010, Bioorganic & medicinal chemistry letters.

Orexin Receptor Antagonists: A New Concept In CNS Disorders?

C. Boss, J. Gatfield, F. Jenck, 2010, ChemMedChem.

The Screening Compound Collection: A Key Asset for Drug Discovery.

C. Boss, T. Kimmerlin, Modest von Korff, 2017, Chimia.

Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.

J. Marfurt, M. Bolli, É. Thorin, 2004, Journal of medicinal chemistry.

Synthesis and Structure of Functionalized Cyclododecadiynes and ‐dienes

C. Boss, R. Keese, 1996 .

SYNTHESIS OF CYCLOALKADIYNES OF VARIOUS RING SIZE

C. Boss, R. Keese, 1997 .

From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs

M. Bolli, C. Brotschi, A. Treiber, 2020, ChemMedChem.

Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure–Activity Relationships, and Sleep‐Promoting Properties in Rats

M. Bolli, C. Brotschi, A. Treiber, 2019, ChemMedChem.

Recent trends in orexin research--2010 to 2015.

C. Boss, C. Roch, 2015, Bioorganic & medicinal chemistry letters.

Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.

C. Brotschi, A. Treiber, T. Sifferlen, 2015, Bioorganic & medicinal chemistry letters.

N-Glycine-sulfonamides as potent dual orexin 1/orexin 2 receptor antagonists.

A. Treiber, R. Koberstein, C. Boss, 2008, Bioorganic & medicinal chemistry letters.

Synthesis of some di- and tricyclic silaalkanes

C. Boss, R. Keese, Zhu Teng, 1997 .

Bis-sulfonamides as endothelin receptor antagonists.

M. Bolli, M. Clozel, W. Fischli, 2003, Bioorganic & medicinal chemistry letters.

The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists.

M. Bolli, M. Clozel, P. Hess, 2003, Bioorganic & medicinal chemistry letters.

Functional Selectivity of G Protein‐Coupled Receptor Ligands: New Opportunities for Drug Discovery. Edited by Kim A. Neve.

C. Boss, 2010 .

Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold.

R. de Kanter, S. Wittlin, C. Boss, 2013, Bioorganic & medicinal chemistry letters.

The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468

J. V. van Gerven, R. de Kanter, M. von Raumer, 2017, The Journal of Pharmacology and Experimental Therapeutics.

The use of physiology-based PK and PD modeling in the discovery of the dual orexin receptor antagonist ACT-541468

J. V. Gerven, A. Treiber, M. Raumer, 2017 .

Inhibitors of aspartic proteases – potential antimalarial agents

Olivier Corminboeuf, C. Grisostomi, T. Weller, 2006 .

X-ray Structure of Plasmepsin II Complexed with a Potent Achiral Inhibitor*

L. Prade, D. Bur, S. Richard-Bildstein, 2005, Journal of Biological Chemistry.

Electron Spin Resonance of Some Vanadium and Titanium Compounds

J. Chien, C. Boss, 1961 .

π-Allyliron Carbonyl Complexes

R. Heck, C. Boss, 1964 .

Diastereoselective Synthesis of Cyclododeca-1,6-diallenes ( = cyclododeca-l,2,6,7-tetraenes)

C. Boss, R. Keese, 1997 .

Polymer reactions. V. Kinetics of autoxidation of polypropylene

James C. W. Chien, J. Chien, C. R. Boss, 1967 .

Vulcanization and Stabilization Studies on Propylene Oxide Rubber

C. Boss, 1975 .

Electron Spin Resonance Spectra of Low Molecular Weight and High Molecular Weight Peroxy Radicals

J. Chien, C. Boss, 1967 .

Polymer reactions. VI. Inhibited autoxidation of polypropylene

J. Chien, C. Boss, 1967 .

Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents.

S. Meyer, W. Fischli, S. Richard-Bildstein, 2003, Current medicinal chemistry.

Effect of volatilization of stabilizers and oxidation products on polypropylene lifetimes

J. Chien, C. Boss, M. Blumberg, 1965 .

UV-triggered Affinity Capture Identifies Interactions between the Plasmodium falciparum Multidrug Resistance Protein 1 (PfMDR1) and Antimalarial Agents in Live Parasitized Cells*

P. Roepe, D. Fidock, M. Akabas, 2013, The Journal of Biological Chemistry.

Identification of a new chemical class of antimalarials.

Zbynek Bozdech, R. Brun, M. Kaiser, 2012, The Journal of infectious diseases.

Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure-activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Part 1.

Johannes Hoecker, C. Brotschi, A. Treiber, 2014, Bioorganic & medicinal chemistry letters.

Discovery and Characterization of ACT‐451840: an Antimalarial Drug with a Novel Mechanism of Action

R. Brun, S. Delahaye, S. Wittlin, 2016, ChemMedChem.

Autoxidation of polypropylene

J. Chien, C. Boss, H. Jabloner, 1972 .

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose–Efficacy Modeling

R. Price, D. Fidock, R. Sinden, 2016, PLoS medicine.

From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.

M. Bolli, C. Boss, J. Gatfield, 2016, Bioorganic & medicinal chemistry letters.

Structure–Activity Relationship, Biological, and Pharmacological Characterization of the Proline Sulfonamide ACT‐462206: a Potent, Brain‐Penetrant Dual Orexin 1/Orexin 2 Receptor Antagonist

C. Brotschi, A. Treiber, T. Sifferlen, 2014, ChemMedChem.

Orexin research: patent news from 2016

C. Boss, C. Roch, 2017, Expert opinion on therapeutic patents.

Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass Spectrometry.

J. V. van Gerven, S. Krähenbühl, D. Zimmer, 2019, Current drug metabolism.

CYP3A4 Catalyzes the Rearrangement of the Dual Orexin Receptor Antagonist Daridorexant to 4‐Hydroxypiperidinol Metabolites

A. Treiber, S. Delahaye, C. Boss, 2023, ChemMedChem.

Discovery and Characterization of ACT‐335827, an Orally Available, Brain Penetrant Orexin Receptor Type 1 Selective Antagonist

A. Treiber, C. Boss, J. Gatfield, 2013, ChemMedChem.

Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934)

C. Boss, C. Roch, 2016, Expert opinion on therapeutic patents.

Orexin receptor antagonists – a patent review (2010 to August 2014)

C. Boss, 2014, Expert opinion on therapeutic patents.

Orexin Receptor Antagonism: A New Principle in Neuroscience

R. Koberstein, T. Weller, T. Sifferlen, 2008 .

Biomedical application of orexin/hypocretin receptor ligands in neuroscience.

C. Boss, F. Jenck, C. Brisbare-Roch, 2009, Journal of medicinal chemistry.

Achiral, Cheap, and Potent Inhibitors of Plasmepsins I, II, and IV

L. Prade, D. Bur, W. Fischli, 2006, ChemMedChem.

Oxygen diffusion limitation in autoxidation of polypropylene

J. Chien, C. Boss, 1966 .

From Bosentan (Tracleer®) to Macitentan (Opsumit®): The Medicinal Chemistry Perspective

M. Bolli, C. Boss, J. Gatfield, 2016 .

Endothelin receptor antagonists: structures, synthesis, selectivity and therapeutic applications.

M. Bolli, C. Boss, T. Weller, 2002, Current Medicinal Chemistry.

Fighting High Molecular Weight in Bioactive Molecules with Sub-Pharmacophore-Based Virtual Screening

Thomas Sander, Modest von Korff, Joël Freyss, 2012, J. Chem. Inf. Model..

20 Years of Medicinal Chemistry - Always Look at the Bright Side (of Life).

C. Boss, 2020, Chimia (Basel).

Synthesis of Plasmepsin II Inhibitors – Potential Antimalarial Agents

C. Boss, M. Huerzeler, Reto Mueller, 2003, Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry.

Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

M. Bolli, M. Iglarz, M. Clozel, 2008, Journal of Pharmacology and Experimental Therapeutics.

Discovery and optimisation of 1-acyl-2-benzylpyrrolidines as potent dual orexin receptor antagonists

M. Bolli, C. Brotschi, A. Treiber, 2015 .

European Medicinal Chemistry Leaders in Industry (EMCL) – On the Status and Future of Medicinal Chemistry Research in Europe **

A. Torrens, M. Bossart, Michael Wagner, 2023, ChemMedChem.